Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Our key strengths include the following:
Sales growth of our commercialized asset.
Proven rare-disease commercialization capabilities.
Internal pipeline of product candidates.
Transgenic Production Platform Technology.
Data exclusivity, know-how and intellectual property.
Our goal is to be a leading biopharmaceutical company focused on offering treatment options for patients with unmet medical needs, focused on rare diseases.
Our three-pillar strategy for achieving our goal is:
Continuing to grow sales of our commercialized asset through further country launches.
Expanding indications for rhC1INH and clinical development and commercialization of new recombinant human proteins using our platform technology.
In-licensing or acquiring drug candidates that are in the late-stages of clinical development and that can potentially leverage our commercial infrastructure.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.